Substituted oxa-diaza-spiro-[5.5]-undecanone derivatives and their use as neurokinin antagonists

Disclosed are oxa-diaza-spiro-[5.5]-undecanone derivatives as represented by the general Formula (I), wherein: R2 is Ar2, Ar2-alkyl, di(Ar2)alkyl, Het1 or Het1-alkyl; X is a covalent bond or a bivalent radical selected from O, S, or NR3; Q is O or NR3; each R3 independently from each other, is hydrogen or alkyl; R1 is selected from the group of Ar1, Ar1-alkyl and di(Ar1)-alkyl; n is an integer, equal to 0, 1 or 2; m is an integer, equal to 1 or 2, provided that if m is 2. then n is 1; Z is a covalent bond or a bivalent radical selected from CH-2 or C(=O); A1, A2, A3 and A4 are each independently from each other selected from the group of CH2CH2, C(=O)O and OC(=O), provided that at least one of C(=O)O and OC(=O) is selected and that =O is in an alpha-position relative to the N-atom; and wherein the remaining substituents are as disclosed herein. Also disclosed is the use of a compound as defined above for the manufacture of a medicament for the treatment and / or prophylaxis of tachykinin mediated conditions, and conditions such as schizophrenia, emesis, anxiety and depression, irritable bowel syndrome. circadian rhythm disturbances, pre-eclampsia, nociceprion, pain, in particular visceral and neuropathic pain, pancreatitis, neurogenic inflammation, asthma, chronic obstructive pulmonary disease and micturition disorders such as urinary incontinence.